Patents by Inventor Kaspar BINZ
Kaspar BINZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230340698Abstract: The present invention relates to designed ankyrin repeat domains with altered surface residues, as well as to proteins comprising such a designed ankyrin repeat domain, nucleic acids encoding such domains or proteins, methods of preparing such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: ApplicationFiled: January 12, 2023Publication date: October 26, 2023Inventors: Hans Kaspar BINZ, Johannes SCHILLING, Patrik FORRER, Victor LEVITSKY, Natalia VENETZ, Marcel WALSER
-
Publication number: 20230243070Abstract: The present invention relates to a method of producing recombinant binding proteins with binding specificity for a peptide-MHC (pMHC) complex. The invention also relates to recombinant binding proteins comprising one, two or more designed repeat domain(s), preferably designed ankyrin repeat domain(s), with binding specificity for a pMHC complex, and to such binding proteins which further comprise a binding agent having binding specificity for a protein expressed on the surface of an immune cell, preferably a T-cell. In addition, the invention relates to nucleic acids encoding such binding proteins or repeat domains, pharmaceutical compositions comprising such binding proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, including cancer, infectious diseases and autoimmune diseases.Type: ApplicationFiled: February 24, 2023Publication date: August 3, 2023Inventors: Victor LEVITSKY, Natalia VENETZ, Marcel WALSER, Hans Kaspar BINZ, Johannes SCHILLING, Patrik FORRER
-
Patent number: 11578427Abstract: The present invention relates to designed ankyrin repeat domains with altered surface residues, as well as to proteins comprising such a designed ankyrin repeat domain, nucleic acids encoding such domains or proteins, methods of preparing such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: GrantFiled: August 12, 2021Date of Patent: February 14, 2023Assignee: MOLECULAR PARTNERS AGInventors: Hans Kaspar Binz, Johannes Schilling, Patrik Forrer, Victor Levitsky, Natalia Venetz, Marcel Walser
-
Patent number: 11332501Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: GrantFiled: November 2, 2018Date of Patent: May 17, 2022Assignee: MOLECULAR PARTNERS AGInventors: Talitha Bakker, Michael T. Stumpp, Hans Kaspar Binz, Douglas Phillips, Ignacio Dolado, Patrik Forrer, Frieder W. Merz, Ivo Sonderegger, Daniel Steiner, Maya Gulotti-Georgieva, Johan Abram Saliba
-
Publication number: 20220106707Abstract: The present invention relates to a method of producing recombinant binding proteins with binding specificity for a peptide-MHC (pMHC) complex. The invention also relates to recombinant binding proteins comprising one, two or more designed repeat domain(s), preferably designed ankyrin repeat domain(s), with binding specificity for a pMHC complex, and to such binding proteins which further comprise a binding agent having binding specificity for a protein expressed on the surface of an immune cell, preferably a T-cell. In addition, the invention relates to nucleic acids encoding such binding proteins or repeat domains, pharmaceutical compositions comprising such binding proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, including cancer, infectious diseases and autoimmune diseases.Type: ApplicationFiled: August 2, 2021Publication date: April 7, 2022Inventors: Victor LEVITSKY, Natalia VENETZ, Marcel WALSER, Kaspar BINZ, Johannes SCHILLING, Patrik FORRER
-
Publication number: 20220064234Abstract: The present invention relates to designed ankyrin repeat domains with altered surface residues, as well as to proteins comprising such a designed ankyrin repeat domain, nucleic acids encoding such domains or proteins, methods of preparing such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: ApplicationFiled: August 12, 2021Publication date: March 3, 2022Inventors: Kaspar BINZ, Johannes SCHILLING, Patrik FORRER, Victor LEVITSKY, Natalia VENETZ, Marcel WALSER
-
Publication number: 20210069293Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: ApplicationFiled: April 9, 2020Publication date: March 11, 2021Inventors: Hans Kaspar BINZ, Patrik FORRER, Michael Tobias STUMPP
-
Patent number: 10646542Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: GrantFiled: November 14, 2017Date of Patent: May 12, 2020Assignee: Molecular Partners AGInventors: Hans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
-
Publication number: 20190263869Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: ApplicationFiled: November 2, 2018Publication date: August 29, 2019Inventors: Talitha Bakker, Michael T. Stumpp, Hans Kaspar Binz, Douglas Phillips, Ignacio Dolado, Patrik Forrer, Frieder W. Merz, Ivo Sonderegger, Daniel Steiner, Maya Gulotti-Georgieva, Johan Abram Saliba
-
Patent number: 10322190Abstract: Improved N-terminal capping modules for designed Ankyrin repeat proteins (DARPins) conferring improved thermal stability to the DARPins are described, as well as nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.Type: GrantFiled: June 23, 2017Date of Patent: June 18, 2019Assignee: Molecular Partners AGInventor: Hans Kaspar Binz
-
Patent number: 10155791Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: GrantFiled: August 26, 2016Date of Patent: December 18, 2018Assignee: Molecular Partners AGInventors: Talitha Bakker, Michael T. Stumpp, Hans Kaspar Binz, Douglas Phillips, Ignacio Dolado, Patrik Forrer, Frieder W. Merz, Ivo Sonderegger, Daniel Steiner, Maya Gulotti-Georgieva, Johan Abram Saliba
-
Publication number: 20180125932Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: ApplicationFiled: November 14, 2017Publication date: May 10, 2018Inventors: HANS KASPAR BINZ, PATRIK FORRER, MICHAEL TOBIAS STUMPP
-
Patent number: 9849158Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: GrantFiled: February 4, 2016Date of Patent: December 26, 2017Assignee: Molecular Partners AGInventors: Hans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
-
Publication number: 20170313748Abstract: Improved N-terminal capping modules for designed Ankyrin repeat proteins (DARPins) conferring improved thermal stability to the DARPins are described, as well as nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.Type: ApplicationFiled: June 23, 2017Publication date: November 2, 2017Inventor: Hans Kaspar BINZ
-
Patent number: 9775912Abstract: New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin.Type: GrantFiled: February 2, 2016Date of Patent: October 3, 2017Assignee: Molecular Partners AGInventors: Daniel Steiner, Hans Kaspar Binz, Maya Gulotti-Georgieva, Frieder W. Merz, Douglas Phillips, Ivo Sonderegger
-
Patent number: 9717802Abstract: Improved N-terminal capping modules for designed Ankyrin repeat proteins (DARPins) conferring improved thermal stability to the DARPins are described, as well as nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.Type: GrantFiled: November 20, 2015Date of Patent: August 1, 2017Assignee: Molecular Partners AGInventor: Hans Kaspar Binz
-
Patent number: 9657287Abstract: A repeat protein from a collection of repeat proteins, wherein each repeat protein of said collection comprises a repeat domain, which comprises a set of consecutive repeat modules, wherein the repeat modules have the same fold and stack tightly to create a superhelical structure having a joint hydrophobic core, wherein each of the repeat modules is derived from one or more repeat units and wherein the repeat units comprise framework residues, which contribute to the folding topology of the repeat unit or contribute to an interaction with a neighboring repeat unit, and target interaction residues, which contribute to an interaction with a target substance, wherein the repeat proteins of the collection differ from other repeat proteins in the collection in at least one amino acid position of the repeat modules is described as are related pharmaceuticals and nucleic acid molecules.Type: GrantFiled: March 3, 2015Date of Patent: May 23, 2017Assignee: Universitat ZurichInventors: Michael Tobias Stumpp, Patrik Forrer, Hans Kaspar Binz, Andreas Pluckthun
-
Publication number: 20160362453Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: ApplicationFiled: August 26, 2016Publication date: December 15, 2016Inventors: Talitha BAKKER, Michael T. STUMPP, Hans Kaspar BINZ, Douglas PHILLIPS, Ignacio DOLADO, Patrik FORRER, Frieder W. MERZ, Ivo SONDEREGGER, Daniel STEINER, Maya GULOTTI-GEORGIEVA, Johan ABRAM SALIBA
-
Publication number: 20160289285Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: ApplicationFiled: April 1, 2016Publication date: October 6, 2016Inventors: Talitha BAKKER, Michael T. STUMPP, Hans Kaspar BINZ, Douglas PHILLIPS, Ignacio DOLADO, Patrik FORRER, Frieder W. MERZ, Ivo SONDEREGGER, Daniel STEINER, Maya GULOTTI-GEORGIEVA, Johan ABRAM SALIBA
-
Patent number: 9458211Abstract: New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.Type: GrantFiled: April 1, 2016Date of Patent: October 4, 2016Assignee: Molecular Partners AGInventors: Talitha Bakker, Michael T. Stumpp, Hans Kaspar Binz, Douglas Phillips, Ignacio Dolado, Patrik Forrer, Frieder W. Merz, Ivo Sonderegger, Daniel Steiner, Maya Gulotti-Georgieva, Johan Abram Saliba